2020
DOI: 10.1002/cam4.2925
|View full text |Cite
|
Sign up to set email alerts
|

Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study

Abstract: Background and Aims: The prognosis of intrahepatic cholangiocarcinoma (ICC) after radical resection is far from satisfactory; however, the clinical value of adjuvant therapy (AT) remains controversial. This multicenter study aimed to evaluate the clinical value of AT and identify potential patients who would be benefited from AT. Methods: Data from ICC patients who underwent radical resection were retrospectively collected from 12 hepatobiliary centers in China between December 2012 and December 2015. Patients… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
28
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
7

Relationship

3
4

Authors

Journals

citations
Cited by 20 publications
(30 citation statements)
references
References 31 publications
0
28
1
Order By: Relevance
“…The optimal p-AT for resected ICC patients has not been determined, and it lacks clinical trial data to support a standard regimen in the postoperative management. Using the data from the multi-center study, we established a nomogram model (23), and found that only patients with "middle risk" could benefit from p-AT, which was confirmed by our recent meta-analysis based on the retrospective studies (34). Currently, adjuvant capecitabine chemotherapy with a duration of 6 months is recommended for patients with resected biliary tract cancer by ASCO guideline (35); while the 8 th NCCN guideline suggests observation or systemic therapy for ICC patients with R0 resection and fluoropyrimidine-/ gemcitabine-based chemotherapy for patients with R1 or pLNM (3).…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…The optimal p-AT for resected ICC patients has not been determined, and it lacks clinical trial data to support a standard regimen in the postoperative management. Using the data from the multi-center study, we established a nomogram model (23), and found that only patients with "middle risk" could benefit from p-AT, which was confirmed by our recent meta-analysis based on the retrospective studies (34). Currently, adjuvant capecitabine chemotherapy with a duration of 6 months is recommended for patients with resected biliary tract cancer by ASCO guideline (35); while the 8 th NCCN guideline suggests observation or systemic therapy for ICC patients with R0 resection and fluoropyrimidine-/ gemcitabine-based chemotherapy for patients with R1 or pLNM (3).…”
Section: Discussionmentioning
confidence: 99%
“…Potential variables associated with the prognosis of HCC patients were determined according to previous studies ( 23 ). Tumor diameter (<5 cm vs. ≥5 cm) and tumor number (single vs. multiple) were categorized according to the American Joint of Cancer Committee (AJCC) system ( 23 ). HBV infection was defined as history of HBV infection, regardless of status of HBsAg and HBV-DNA ( 23 ).…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…ICC makes up approximately 5% of all primary liver cancer cases, and prognosis is very poor because of the possibility of relapse both outside and inside the liver, even when a patient undergoes liver resection at an early stage (12,13). Therefore, stratification of ICC patients based on the risk of recurrence would be helpful for identifying candidates for postoperative adjuvant therapy (14,15). In addition to clinicopathological findings (16,17) and surgical procedures (18,19), various types of predictive marker, such as aspartate aminotransferase/neutrophil ratio (20), platelet/ lymphocyte ratio (21), albumin/gGTP ratio (22), and neutrophil/lymphocyte ratio (23), have been reported as being negatively associated with patient survival after resection of ICC.…”
Section: Introductionmentioning
confidence: 99%